Arrowhead Pharmaceuticals (ARWR) said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases.
The second part of the phase 1/2 clinical study also showed reductions of 85% in AH50 and 100% in Wieslab AP, which are both markers of alternative pathway complement activity, in patients with IgA nephropathy, the company said.
Arrowhead also reported that the therapy was generally well tolerated by the patients, with no serious or severe treatment adverse events.
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of adult healthy volunteers and adult patients with complement-mediated renal disease.
The company said it plans to present additional results at an upcoming medical meeting later this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。